Medicine · 2017
New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takizawa Tsubasa, Kojima Marenori, Suzuki Shigeaki, Osada Takashi, Kitagawa Satoshi, Nakahara Jin, Takahashi Shinichi, Suzuki Norihiro
Аннотация
RATIONALE: Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer.
PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks.
DIAGNOSES: Ocular MG was confirmed by a positive serum anti-acetylcholine receptor antibody test.
INTERVENTIONS: Treatment with high-dose methylprednisolone pulse therapy was given, after insufficient treatment with pyridostigmine bromide and 10 mg/d prednisolone.
OUTCOMES: Symptoms resolved completely 12 days after high-dose methylprednisolone pulse therapy.
LESSONS: Intravesical BCG could be listed as a novel drug that may induce a new onset of MG along with drugs such as D-penicillamine and immune checkpoint inhibitors.
PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks.
DIAGNOSES: Ocular MG was confirmed by a positive serum anti-acetylcholine receptor antibody test.
INTERVENTIONS: Treatment with high-dose methylprednisolone pulse therapy was given, after insufficient treatment with pyridostigmine bromide and 10 mg/d prednisolone.
OUTCOMES: Symptoms resolved completely 12 days after high-dose methylprednisolone pulse therapy.
LESSONS: Intravesical BCG could be listed as a novel drug that may induce a new onset of MG along with drugs such as D-penicillamine and immune checkpoint inhibitors.